JO3580B1 - أجسام مضادة لكيموكين elr+ cxc شامل - Google Patents

أجسام مضادة لكيموكين elr+ cxc شامل

Info

Publication number
JO3580B1
JO3580B1 JOP/2014/0058A JOP20140058A JO3580B1 JO 3580 B1 JO3580 B1 JO 3580B1 JO P20140058 A JOP20140058 A JO P20140058A JO 3580 B1 JO3580 B1 JO 3580B1
Authority
JO
Jordan
Prior art keywords
elr
pan
antibodies
cxc chemokine
chemokine antibodies
Prior art date
Application number
JOP/2014/0058A
Other languages
English (en)
Inventor
Streetman Boyles Jeffrey
Ann Strifler Beth
Brautigam Beidler Catherine
Ryan Witcher Derrick
Kay Kikly Kristine
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3580B1 publication Critical patent/JO3580B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

يتعلق الاختراع الحالي بأجسام مضادة ترتبط تحديدًا بالكيموكينات البشرية السبعة ELR+ CXC. تفيد الأجسام المضادة وفقًا للاختراع في علاج العديد من الأمراض الالتهابية/ذاتية المناعة، مثل مرض التهاب الأمعاء (IBD)، والصدفية اللويحية، والبثار الراحي الأخمصي؛ والسرطان، مثل سرطان الكلى أو سرطان المبيض.
JOP/2014/0058A 2013-03-15 2014-02-27 أجسام مضادة لكيموكين elr+ cxc شامل JO3580B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792800P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
JO3580B1 true JO3580B1 (ar) 2020-07-05

Family

ID=50343858

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0058A JO3580B1 (ar) 2013-03-15 2014-02-27 أجسام مضادة لكيموكين elr+ cxc شامل

Country Status (36)

Country Link
EP (3) EP2970447B1 (ar)
JP (1) JP6105146B2 (ar)
KR (1) KR101745230B1 (ar)
CN (2) CN109134652B (ar)
AP (1) AP2015008731A0 (ar)
AR (2) AR094960A1 (ar)
AU (1) AU2014237898B2 (ar)
CA (1) CA2901468C (ar)
CL (1) CL2015002531A1 (ar)
CY (1) CY1120459T1 (ar)
DK (1) DK2970447T3 (ar)
EA (1) EA029965B1 (ar)
ES (2) ES2675404T3 (ar)
HK (1) HK1212714A1 (ar)
HR (1) HRP20181047T1 (ar)
HU (1) HUE038834T2 (ar)
IL (2) IL241167B (ar)
JO (1) JO3580B1 (ar)
LT (1) LT2970447T (ar)
MA (1) MA38413A1 (ar)
ME (1) ME03094B (ar)
MX (1) MX364831B (ar)
MY (1) MY171213A (ar)
NZ (1) NZ711704A (ar)
PE (2) PE20191480A1 (ar)
PH (1) PH12015502090B1 (ar)
PL (1) PL2970447T3 (ar)
PT (1) PT2970447T (ar)
RS (1) RS57291B1 (ar)
SG (1) SG11201507686TA (ar)
SI (1) SI2970447T1 (ar)
TN (1) TN2015000377A1 (ar)
TR (1) TR201807613T4 (ar)
TW (1) TWI612059B (ar)
UA (1) UA116008C2 (ar)
WO (1) WO2014149733A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160021125A (ko) * 2013-05-17 2016-02-24 쌩뜨레 나티오날 데 라 르세르쉬 생띠끄 (씨. 엔. 알. 에스) 항-cxcl1, cxcl7 및 cxcl8 항체 및 이들의 용도
WO2019036605A2 (en) * 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
CA3084370A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
KR102049180B1 (ko) * 2018-04-02 2019-11-26 고려대학교 산학협력단 체세포에서 유도 만능 줄기세포로의 역분화 유도용 조성물 및 이를 이용한 역분화 유도방법
TWI737000B (zh) * 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體
KR20220054689A (ko) 2019-10-15 2022-05-03 일라이 릴리 앤드 캄파니 재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주
CN115335406A (zh) * 2020-02-12 2022-11-11 伊莱利利公司 抗体或抗原-结合片段的结晶
TW202206457A (zh) 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2007107003A1 (en) * 2006-03-22 2007-09-27 Osteopharm Inc. Markers for the diagnosis, monitoring and prognosis of osteoporosis and for assessing the risk for osteoporosis and for osteoporotic fractures
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
KR101667944B1 (ko) * 2007-08-29 2016-10-20 사노피 인간화된 항-ｃｘｃｒ5 항체, 이의 유도체 및 이들의 용도
GB0806812D0 (en) * 2008-04-15 2008-05-14 Univ Leuven Kath Citrullinated cytokines
MX2010012435A (es) * 2008-05-14 2011-05-03 Lilly Co Eli Anticuerpos anti-cxcr4.
US8313747B2 (en) * 2009-08-28 2012-11-20 Vlst Corporation Antikine antibodies that bind to multiple CC chemokines
JP2011097867A (ja) * 2009-11-05 2011-05-19 Kurume Univ 脊柱靱帯骨化症のマーカーペプチド
US20120315267A1 (en) * 2010-02-09 2012-12-13 Glaxosmithkline Llc Novel uses
WO2013166099A1 (en) * 2012-05-01 2013-11-07 Glaxosmithkline Llc Novel antibodies

Also Published As

Publication number Publication date
CN109134652A (zh) 2019-01-04
PE20151531A1 (es) 2015-10-28
MX364831B (es) 2019-05-08
TW201520226A (zh) 2015-06-01
IL269387A (en) 2019-11-28
MX2015013053A (es) 2016-05-18
AP2015008731A0 (en) 2015-09-30
EA029965B1 (ru) 2018-06-29
CA2901468C (en) 2018-02-20
PH12015502090A1 (en) 2016-01-18
ES2675404T3 (es) 2018-07-11
CL2015002531A1 (es) 2016-06-17
PE20191480A1 (es) 2019-10-18
CY1120459T1 (el) 2019-07-10
JP6105146B2 (ja) 2017-03-29
CN105143259B (zh) 2018-09-21
IL241167B (en) 2019-10-31
IL241167A0 (en) 2015-11-30
CN105143259A (zh) 2015-12-09
AU2014237898A1 (en) 2015-08-20
KR101745230B1 (ko) 2017-06-08
EP2970447B1 (en) 2018-05-16
IL269387B (en) 2021-05-31
EP3348569A1 (en) 2018-07-18
KR20150119155A (ko) 2015-10-23
EA201591514A1 (ru) 2016-03-31
SG11201507686TA (en) 2015-10-29
CN109134652B (zh) 2022-05-24
MY171213A (en) 2019-10-02
AU2014237898A8 (en) 2015-08-27
HK1212714A1 (zh) 2016-06-17
SI2970447T1 (en) 2018-06-29
NZ711704A (en) 2019-12-20
HRP20181047T1 (hr) 2018-08-24
RS57291B1 (sr) 2018-08-31
TN2015000377A1 (en) 2017-01-03
PT2970447T (pt) 2018-08-07
UA116008C2 (uk) 2018-01-25
EP2970447A1 (en) 2016-01-20
TWI612059B (zh) 2018-01-21
ES2769123T3 (es) 2020-06-24
PH12015502090B1 (en) 2016-01-18
EP3348569B1 (en) 2019-11-27
ME03094B (me) 2019-01-20
DK2970447T3 (en) 2018-06-18
PL2970447T3 (pl) 2018-10-31
JP2016512026A (ja) 2016-04-25
HUE038834T2 (hu) 2018-11-28
MA38413A1 (fr) 2017-10-31
AR094960A1 (es) 2015-09-09
BR112015020174A2 (pt) 2017-08-29
AR125831A2 (es) 2023-08-16
CA2901468A1 (en) 2014-09-25
AU2014237898B2 (en) 2016-05-05
LT2970447T (lt) 2018-07-25
WO2014149733A1 (en) 2014-09-25
EP3608336A1 (en) 2020-02-12
TR201807613T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
PH12015502090B1 (en) Pan-elr+cxc chemokine antibodies
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2019012233A (es) Anticuerpos anti-sirpa.
EA202091540A1 (ru) Антитела к lilrb2
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
MX2018009700A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2022007522A (es) Anticuerpos anti-cd27.
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA201790060A1 (ru) Биспецифические cd33- и cd3-связывающие белки
MX2015011957A (es) Anticuerpos biespecificos anti-tnf-anti-il-17.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2019015042A (es) Regimen de dosificacion.
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
IN2013MU01918A (ar)